Volumetric assessment of the responsiveness of pigment epithelial detachments in neovascular age-related macular degeneration to intravitreal bevacizumab

Retina

Volumn 36, Issue 2, 2016, Pages 264-271

  Or, Chris ^a   Chui, Lica ^a   Fallah, Nader ^a   Forooghian, Farzin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

age related macular degeneration; intravitreal bevacizumab; neovascular; optical coherence tomography; pigment epithelial detachment; volumetric analysis

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MALE; RETINA DETACHMENT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT RESPONSE; VISUAL ACUITY; VOLUMETRY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84957440123     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000795     Document Type: Article

References (34)

1. Sulzbacher F, Kiss C, Kaider A, et al. Correlation of SD-OCT features and retinal sensitivity in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2012;53: 6448-6455.
2. Clemens CR, Krohne TU, Charbel Issa P, et al. High-resolution optical coherence tomography of subpigment epithelial structures in patients with pigment epithelium detachment secondary to age-related macular degeneration. Br J Ophthalmol 2012;96:1088-1091.
3. Gass JD, Norton EW, Justice J Jr. Serous detachment of the retinal pigment epithelium. Trans Am Acad Ophthalmol Oto-laryngol 1966;70:990-1015.
4. Mrejen S, Sarraf D, Mukkamala SK, Freund KB. Multimodal imaging of pigment epithelial detachment: a guide to evaluation. Retina 2013;33:1735-1762.
5. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine-green videoangiography of occult choroidal neo-vascularization. Ophthalmology 1994;101:1727-1735; discussion 1735-1727.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
7. Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
8. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-2548.
9. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intra-vitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
10. Freeman WR, Kozak I, Yuson RM, et al. Prognosti implications of pigment epithelial detachment in bevacizumab (avas-tin)-treated eyes with age-related macular degeneration and choroidal neovascularization. Retina 2011;31:1812-1818.
11. Golbaz I, Ahlers C, Stock G, et al. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 2011;52: 1599-1605.
12. Suzuki M, Nagai N, Izumi-Nagai K, et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol 2014;98: 1186-1191.
13. Ersoy L, Ristau T, Kirchhof B, Liakopoulos S. Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 2014; 252:889-897.
14. Hoerster R, Muether PS, Sitnilska V, et al. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion. Retina 2014;34:1767-1773.
15. Baba T, Kitahashi M, Kubota-Taniai M, et al. Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40. Ophthalmologica 2012;228:102-109.
16. Ozkaya A, Alkin Z, Osmanbasoglu OA, et al. Intravitreal ranibizumab for neovascular age-related macular degeneration patients with good baseline visual acuity and the predictive factors for visual outcomes. J Fr Ophtalmol 2014;37: 280-287.
17. Doguizi S, Ozdek S. Pigment epithelial tears associated with anti-VEGF therapy: incidence, long-term visual outcome, and relationship with pigment epithelial detachment in age-related macular degeneration. Retina 2014;34:1156-1162.
18. Chiang A, Chang LK, Yu F, Sarraf D. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina 2008;28:1265-1269.
19. Ach T, Hoeh AE, Ruppenstein M, et al. Intravitreal bevacizu-mab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Retina 2010;30:1420-1425.
20. Penha FM, Rosenfeld PJ, Gregori G, et al. Quantitative imaging of retinal pigment epithelial detachments using spectral-domain optical coherence tomography. Am J Ophthalmol 2012;153:515-523.
21. Penha FM, Gregori G, Garcia Filho CA, et al. Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy. Retina 2013;33:459-466.
22. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intra-vitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012;32:434-457.
23. Patel KH, Chow CC, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) 2013;27:663-667; quiz 668.
24. Grewal DS, Gill MK, Sarezky D, et al. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond) 2014;28:895-899.
25. Thorell MR, Nunes RP, Chen GW, et al. Response to afliber-cept after frequent re-treatment with bevacizumab or ranibizu-mab in eyes with neovascular AMD. Ophthalmic Surg Lasers Imaging Retina 2014;45:526-533.
26. Gharbiya M, Iannetti L, Parisi F, et al. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neo-vascular age-related macular degeneration. Biomed Res Int 2014;2014:273754.
27. Elshout M, van der Reis MI, Webers CA, Schouten JS. The cost-utility of aflibercept for the treatment of age-related mac-ular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefes Arch Clin Exp Ophthalmol 2014;252:1911-1920.
28. Dakin HA, Wordsworth S, Rogers CA, et al. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open 2014;4:e005094.
29. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-290.
30. De Salvo G, Vaz-Pereira S, Keane PA, et al. Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 2014;158:1228-1238.
31. Barikian A, Mahfoud Z, Abdulaal M, et al. Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration. Am J Oph-thalmol 2014;159:131-137.
32. Forooghian F, Kertes PJ, Eng KT, et al. Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. Invest Ophthalmol Vis Sci 2010;51:2388-2392.
33. Tolentino MJ, Dennrick A, John E, Tolentino MS. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration. Expert Opin Investig Drugs 2014;24:1-17.
34. Ho J, Adhi M, Baumal C, et al. Agreement and reproducibility of retinal pigment epithelial detachment volumetric measurements through optical coherence tomography. Retina 2015;35: 467-472.